Clinical Research Directory

Inclusion Criteria: FOR DS-TB COHORTS (2HPMZ/2HPM and 2HRZE/4HR): * Age 18 years or older * Bacteriologically confirmed drug-susceptible pulmonary tuberculosis * Newly diagnosed, not previously treated (or treated less than 1 month) * Willing and able to provide written informed consent * Residing in one of the four pilot regions of Kazakhstan FOR TBI COHORT (1HP): * Age 18 years or older * Diagnosed with tuberculosis infection * No evidence of active tuberculosis disease * Willing and able to provide written informed consent * Residing in one of the four pilot regions of Kazakhstan Exclusion Criteria: FOR DS-TB COHORTS: * Confirmed or suspected drug-resistant tuberculosis (rifampicin-resistant tuberculosis (RR-TB) or multidrug-resistant tuberculosis (MDR-TB)) * Extrapulmonary tuberculosis as the sole manifestation * Pregnancy or breastfeeding at time of enrollment * Severe hepatic impairment (alanine aminotransferase (ALT)/aspartate aminotransferase (AST) \>3x upper limit of normal) * Known hypersensitivity to rifapentine, isoniazid, moxifloxacin, or pyrazinamide * corrected QT interval (QTc) interval \>500 ms on baseline electrocardiogram (ECG) * Currently receiving medications with significant interactions contraindicated with study regimens FOR TBI COHORT: * Active tuberculosis disease * Previous treatment for TB or TBI within the past 2 years * Pregnancy at time of enrollment * Severe hepatic impairment * Known hypersensitivity to rifapentine or isoniazid